Uncategorized – Page 330

Prologue Ventures: Revolutionizing Viral Protein Drug Development with $50 Million Investment

1 year ago talkbio0Tagged Biotechnology, Drug Development, healthcare innovation, Investments, Prologue Ventures, Viral Proteins

Prologue Ventures, viral protein drugs, $50 million investment, drug development, biotechnology, healthcare innovation.

ADC Therapeutics Showcases Promising Zynlonta Data in Marginal Zone Lymphoma and Secures $105M in Funding

1 year ago talkbio0Tagged Antibody-Drug Conjugates, Biotechnology, Cancer Therapeutic Procedure, Clinical Trials, Health care facility, Mucosa-Associated Lymphoid Tissue Lymphoma, Sales - occupational activity, therapeutic autologous dendritic cells, Zynlonta

ADC Therapeutics, Zynlonta, marginal zone lymphoma, share sale, funding, cancer treatment, antibody-drug conjugate, clinical trials, biotechnology, healthcare.

Novo, Gates, and Wellcome Join Forces with $300 Million Initiative to Tackle Global Infectious Diseases

1 year ago talkbio0Tagged Collaboration, Communicable Diseases, development aspects, Global Health, Holdings, Melinda, Microbicides, pandemic preparedness, research, Resistance (Psychotherapeutic), Trust (Social Behavior), Wellcome

Novo Holdings, Bill & Melinda Gates Foundation, Wellcome Trust, infectious diseases, global health, pandemic preparedness, antimicrobial resistance, research and development, funding, collaboration.

Chiesi Invests Heavily in Gossamer’s Promising Pulmonary Hypertension Treatment

1 year ago talkbio0Tagged Cardiovascular Diseases, Chiesi, Clinical Trials, Collaboration, Drug Development, GD-001, Gossamer, Investments, Pulmonary Hypertension

Chiesi, Gossamer, pulmonary hypertension, drug development, investment, collaboration, GD-001, clinical trials, cardiovascular diseases.

Pfizer Appoints Citi Analyst Andrew Baum as New Strategy Chief

1 year ago talkbio0Tagged Andrew Baum, Chief, Citi, Drug Industry, Leadership Change, Pfizer, Strategic Planning, Strategy

Pfizer, Andrew Baum, Citi analyst, strategy chief, pharmaceutical industry, leadership change, strategic planning.

GlycoMimetics’ Uproleselan Fails to Meet Primary Endpoint in Leukemia Clinical Trial

1 year ago talkbio0Tagged Clinical Trials, GlycoMimetics, leukemia, Primary Endpoint, Stock Market Reaction, Uproleselan

GlycoMimetics, Uproleselan, Leukemia, Clinical Trial, Primary Endpoint, Stock Market Reaction

AstraZeneca Strengthens Partnership with Cellectis in Cell and Gene Therapy Advancement

1 year ago talkbio0Tagged AstraZeneca, Biotechnology, Cell Therapy, Cellectis, development aspects, Discover, gene therapy, Health care facility, innovation, Investments, Medical Research activity, Papillary thyroid carcinoma, Partnership, stake

AstraZeneca, Cellectis, cell therapy, gene therapy, partnership, stake, discovery, pact, biotechnology, healthcare, investment, innovation, medical research, therapeutic development.